Our animal study revealed that HEGU inhibited the expression of Ki67, CD45, CD31, VEGF-A, HIF-1α, iNOS, and COX-2 in tumor tissues (Figure 1) and plasma levels of VEGF-A, MMP-9, ICAM, and VACM (Figure 2). This evidence concerns the gene PTGS2 and neoplasm.